Opposing effects of ERK and p38‐JNK MAP kinase pathways on formation of prions in GT1‐1 cells
Authors:
- 29 September 2008
- journal article
- Published by Wiley in The FASEB Journal
- Vol. 23 (2) , 613-622
Abstract
Brain‐derived neurotrophic factor, which activates the extracellular regulated kinase (ERK) pathway, increases formation of prions in scrapie‐infected gonadotropin‐releasing hormone (GT1–1) cells. This indicates that conversion of the cellular prion protein PrP to its pathogenic isoform, PrP Sc , can be regulated by physiological stimuli acting on specific signal transduction pathways. In the present study, we examined the involvement of different mitogen‐activated protein (MAP) kinase cascades and the cAMP‐PKA pathway in formation of proteinase K‐resistant PrP Sc (rPrP Sc ). Long‐term depolarization of GT1‐1 cells infected with the Rocky Mountain Laboratory strain of scrapie increased the formation of rPrP Sc . This effect was associated to ERK activation and was blocked by the MAPK/ERK kinase (MEK) inhibitor U0126. Treatment with forskolin caused a similar increase in rPrP Sc formation that was prevented by the protein kinase A (PKA) inhibitor H89. Both depolarization and forskolin treatment were accompanied by increased phosphorylation of the S6 ribosomal protein, while phosphorylation of histone H3 occurred only after forskolin treatment. Inhibitors of p38‐ and c‐Jun NH 2 ‐terminal kinase (JNK) promoted the formation of rPrP Sc , in contrast to the clearance of rPrP Sc produced by inhibitors of the ERK pathway. Thus, the ERK and the p38‐JNK MAP kinase pathways appear to exert opposing effects on rPrP Sc formation, suggesting that balances between these intracellular signaling cascades may regulate replication of prions.— Nordström, E., Fisone, G., Kristensson, K. Opposing effects of ERK and p38‐JNK MAP kinase pathways on formation of prions in GT1‐1 cells. FASEB J. 23, 613–622 (2009)Keywords
This publication has 53 references indexed in Scilit:
- Isolation and Characterization of a Proteinase K-Sensitive PrPSc FractionBiochemistry, 2006
- Emerging Pharmacotherapies for Creutzfeldt-Jakob DiseaseArchives of Neurology, 2006
- Approaches to Therapy of Prion DiseasesAnnual Review of Medicine, 2005
- Protease-Sensitive Scrapie Prion Protein in Aggregates of Heterogeneous SizesBiochemistry, 2002
- Intracellular re‐routing of prion protein prevents propagation of PrPSc and delays onset of prion diseaseThe EMBO Journal, 2001
- Eight prion strains have PrPSc molecules with different conformationsNature Medicine, 1998
- Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagationProceedings of the National Academy of Sciences, 1997
- Prion propagation in mice expressing human and chimeric PrP transgenes implicates the interaction of cellular PrP with another proteinCell, 1995
- Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform [published erratum appears in J Cell Biol 1995 Jul;130(2):501]Journal of Cell Biology, 1995
- Transmission of Creutzfeldt-Jakob disease from humans to transgenic mice expressing chimeric human-mouse prion protein.Proceedings of the National Academy of Sciences, 1994